AstraZeneca stock price gains as Trump considers fast-tracking their COVID-19 vaccine

Shares of AstraZeneca PLC (LON: AZN) gained over 1% on reports that the U.S. government considers fast-tracking the approval for Astrazeneca’s coronavirus vaccine in the States before the forthcoming presidential elections, according to a report by the Financial Times.  Fundamental analysis: Unrealistic scenario? The FT report said that President Donald Trump is considering several options, one of them including the FDA’s approval for the emergency use of Astrazeneca’s vaccine which was developed in partnership with Oxford University.   If it happens, the authorization could be predicated on a small study performed by AstraZeneca which includes 10,000 volunteers in the UK, while